This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated September 2026 quarter revenue Rs 2,532.64 lakh, up 63%; profit after tax up 153%
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated unaudited quarter ended 30 September 2026: revenue from operations was Rs 2,532.64 lakh versus Rs 1,549.73 lakh a year earlier, up 63.4%; profit after tax was Rs 414.71 lakh versus Rs 163.85 lakh, up 153.1%. Operating profit before interest, tax, depreciation and amortisation was 25.6% of revenue versus 14.5%. Consolidated half year: revenue rose 47.3% to Rs 4,916.56 lakh and profit after tax rose 97.0% to Rs 663.82 lakh.
Strong revenue, profit and margin growth may support the stock, but rising finance costs and borrowings are risks for shareholders.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹25.33 Cr | ₹18.50 Cr | +36.9% |
| Operating profit | ₹5.43 Cr | ₹5.03 Cr | +8.0% |
| Profit after tax | ₹4.15 Cr | ₹4.64 Cr | −10.6% |
| EBITDA margin | 25.6% | 28.4% | −2.8 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.